Inc. and ONO Pharmaceutical Co., Ltd. Are allergic to cenobamate or any of the other ingredients in XCOPRI. Have a genetic problem (called Familial Short QT syndrome) that affects the electrical ...

It’s not known whether Xcopri (cenobamate) is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...

According to a real-world study, cenobamate was effective in patients with drug-resistant epilepsy (DRE), with 49.3% of patients achieved a 50% or greater reduction in seizure frequency at 3 months.

Cenobamate was originally developed by South Korean biotech SK Biopharmaceuticals, and was approved as Xcopri in the US in 2019. The drug made almost $17 million in US sales in the third quarter.

SEOUL, Jan. 15 (Yonhap) -- SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major South American biopharma, Eurofarma, in the ...

Epilepsy patients and advocates are calling on the Saskatchewan government to provide public coverage for a new anti-seizure ...

The articles, authored by several world-renowned epilepsy experts, provide an in-depth overview of the latest in epilepsy treatment, including XCOPRI® (cenobamate tablets) CV and data for these ...

Addressing common treatment barriers to adopting cenobamate and other new antiseizure medications: Prematurely discontinuing new ASMs like XCOPRI may lead to an inadequate assessment of efficacy.